GLUE Insider Anthony Manning Sells $231K of Stock
Insider Anthony Manning sold a significant number of shares in Monte Rosa Therapeutics, reflecting recent trading activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Anthony Manning sold 10,000 shares of Monte Rosa Therapeutics, Inc. ($GLUE) at an average price of $23.11, worth about $231,100, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GLUE is down 2.7% after 1 week, down 9.8% after 1 month and down 59.2% to date (from the $23.90 close on Jun 29, 2026).
GLUE
Monte Rosa Therapeutics, Inc.
Key Points
- On June 29, 2026, Anthony Manning sold 10,000 shares of Monte Rosa Therapeutics (GLUE) for approximately $231,100 at a price of $23.11 each.
- The stock is currently trading at $24.20, close to its 52-week high of $25.77, highlighting strong market interest.
- Analysts maintain a consensus strong buy rating with a mean price target of $28.50, indicating confidence in the company's future.
Get $GLUE trade alerts by text
We text you when insiders, Congress or big funds trade $GLUE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Monte Rosa Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
On June 29, 2026, Anthony Manning, a key insider at Monte Rosa Therapeutics, Inc. (GLUE), sold 10,000 shares for about $231,100. The shares were sold at a price of $23.11 each. This transaction reflects Manning's recent activity, as he had just purchased shares earlier on the same day.
What Changed in Manning's Position
Manning's sale of 10,000 shares comes after he acquired the same amount at $4.16 each earlier in the day. This sale indicates a significant change in his position, moving from owning shares to liquidating them.
Institutional Activity
No other funds have reported changes in their positions in Monte Rosa Therapeutics recently, so this insider sale stands out in the current trading environment.
How Monte Rosa Therapeutics, Inc. Stock Has Traded
Monte Rosa Therapeutics is currently trading at $24.20, which is near its 52-week high of $25.77. The stock has shown strong performance recently, reflecting growing investor interest. The company has a market cap of approximately $1.05 billion, and it has been gaining traction in the biotechnology sector.
Recent Earnings
In its latest earnings report, Monte Rosa Therapeutics posted revenue of $28.7 million, though it experienced a decline in revenue growth. The next earnings report is set for November 5, 2026, which investors will be watching closely for further insights.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
On June 29, 2026, Anthony Manning sold 10,000 shares at $23.11 each, totaling approximately $231,100. Earlier that day, he had also purchased 10,000 shares at $4.16 each. Filip Janku, the Chief Medical Officer, also engaged in trading on the same day, selling 6,000 shares at $22.95 each. Janku had previously bought shares on June 23, showing a pattern of active trading within the company’s leadership.
Analysts Set New Price Targets
Analysts remain optimistic about Monte Rosa Therapeutics. On October 1, 2026, HC Wainwright & Co. initiated coverage with a buy rating and a target price of $25. On October 5, they reiterated this rating. Other firms like Wedbush and Guggenheim also maintain positive ratings, with price targets ranging from $27 to $28.
What Monte Rosa Therapeutics, Inc. Does
Monte Rosa Therapeutics focuses on developing innovative small molecule medicines that target specific proteins in the body. This strategic direction is crucial as the company seeks to advance its clinical programs in various therapeutic areas, including oncology and autoimmune diseases.
What's Ahead for Monte Rosa Therapeutics, Inc.
Investors will be watching for the upcoming earnings report on November 5, 2026, to gauge the company's financial health and outlook. The recent insider transactions may also provide insights into the confidence levels among the company's leadership. As always, the 13F filings reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Anthony Manning's Form 4 filing on $GLUE (Jun 29, 2026). Find the original filing: GLUE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts